Jci_page_head_homepage_01 Jci_page_head_homepage_02
Paul T. Brinkkoetter, Paul Olivier, Jimmy S. Wu, Scott Henderson, Ronald D. Krofft, Jeffrey W. Pippin, David Hockenbery, James M. Roberts, Stuart J. Shankland
Published in Volume 119, Issue 10
J Clin Invest. 2009; 119(10):3089–3101 doi:10.1172/JCI37978
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 12
Proposed model showing the effects of Cdk5 upon activation by cyclin I and p35.

Cdk5 is activated by cyclin I and p35. The pathways by which Cdk5 confers a prosurvival function depend on the activator. Cyclin I–Cdk5 leads to phosphorylation of MEK1/2, and subsequently, ERK1/2, leading to increased mRNA and protein levels for the prosurvival proteins Bcl-2 and Bcl-XL. In contrast, p35-Cdk5 increases Bcl-2 protein levels by posttranslational modification (30). p35-Cdk5 has no effect on Bcl-XL levels. The dual activation of Cdk5 by cyclin I and p35 ensures that maximal survival pathways are operative in terminally differentiated cells.